The ECHDC1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population in which the ECHDC1 gene has been disrupted in the HT29 human colorectal adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted gene disruption, allowing researchers to investigate the functional consequences of ECHDC1 loss in a colorectal cancer context. The polyclonal nature ensures a representation of diverse editing events, enabling studies of gene function without the bias of a single clonal isolate. The knockout model is suitable for a wide range of biochemical, metabolic, and phenotypic assays.
The HT29 cell line, derived from a primary colorectal adenocarcinoma, is a widely used epithelial model in cancer research. It harbors well-characterized mutations in the tumor suppressor genes APC and TP53, which are common in colorectal tumors. These mutations contribute to aberrant Wnt signaling and genomic instability, making HT29 cells a relevant system for studying colorectal cancer biology. The cells exhibit an epithelial morphology and retain the capacity to differentiate under specific conditions, providing a versatile platform for investigating metabolic dependencies and therapeutic sensitivities.
ECHD1 encodes an ethylmalonyl-CoA decarboxylase that catalyzes the conversion of ethylmalonyl-CoA to butyryl-CoA, a key step linking propionyl-CoA metabolism to mitochondrial fatty acid ??-oxidation. The enzyme also possesses enoyl-CoA hydratase/isomerase activity. ECHDC1 expression is regulated by peroxisome proliferator-activated receptor alpha (PPAR??) and PPAR?? coactivator 1-alpha (PGC-1??) in response to nutritional status and fatty acid availability. Downstream, ECHDC1 generates butyryl-CoA, which can feed into the ??-oxidation spiral and ultimately support the tricarboxylic acid (TCA) cycle. The protein interacts with the mitochondrial trifunctional protein subunits HADHA and HADHB, propionyl-CoA carboxylase, and methylmalonyl-CoA mutase, integrating it within the broader network of mitochondrial one-carbon metabolism and propionate handling. Representative pathway components include ETHE1, which processes sulfide, and downstream metabolites propionyl-CoA and succinyl-CoA, highlighting the enzyme??s role in avoiding toxic intermediate accumulation.
In HT29 colon cancer cells, ECHDC1 knockout is predicted to disrupt butyryl-CoA production, potentially altering butyrate metabolism. Butyrate, a short-chain fatty acid produced by gut microbiota, is a histone deacetylase inhibitor that promotes differentiation and apoptosis in colonocytes. Impaired butyrate utilization due to ECHDC1 loss could shift cellular metabolism, impacting energy homeostasis and epigenetic regulation. This knockout model enables the dissection of how mitochondrial fatty acid oxidation and propionyl-CoA metabolism contribute to colorectal cancer cell proliferation, survival, and response to metabolic stress. By uncoupling ethylmalonyl-CoA decarboxylation from ??-oxidation, researchers can explore metabolic vulnerabilities specific to cancer cells with altered mitochondrial function, such as those found in the tumor microenvironment.
The ECHDC1 Knockout HT29 Polyclonal Cells are a valuable tool for investigating the role of ECHDC1 in colorectal cancer metabolism. Typical applications include examining butyrate-induced growth inhibition and differentiation, assessing mitochondrial respiratory capacity using Seahorse analysis, and profiling acyl-CoA metabolites via liquid chromatography-mass spectrometry (LC-MS). The cells can be used in combination with metabolic inhibitors to identify synthetic lethal interactions or to study the metabolic reprogramming that supports tumor growth under nutrient-limited conditions. Assays such as Western blotting and RT-qPCR enable validation of ECHDC1 disruption, while immunofluorescence can reveal mitochondrial morphology changes. This knockout population thus serves as a robust platform for functional genomics and drug discovery in colorectal cancer. For additional model details or customized services, please contact Ascent Research.
